Phaseline

Companies › Shanghai Pharmaceuticals Holding

Shanghai Pharmaceuticals Holding: clinical trials, targets and expected readouts

6 active drug programs in 10 registered trials: 5 Phase 2, 5 Phase 1; Oncology, Neurology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SPH4336–Phase 2Locally Advanced or Metastatic Breast Cancer; Breast Cancer Brain Metastases; Advanced Solid TumorsDec 2026
LT3001–Phase 2Acute Ischemic StrokeDec 2026
SPH5030
HER2 tyrosine kinase inhibitor
–Phase 2Biliary Tract or Colorectal Cancer With Her2-positive/MutatedDec 2026
SPH9788–Phase 1Healthy ParticipantsDec 2026
T3011
Intratumoral immunotherapy agent
–Phase 1Advanced Melanoma; Advanced Solid TumorsDec 2026
SPH7485–Phase 1Advanced Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05744687SPH4336Phase 2Locally Advanced or Metastatic Breast CancerOncologyMay 2026
NCT06214156T3011Phase 1Advanced MelanomaOncologySep 2026
NCT05860465SPH4336Phase 2Locally Advanced or Metastatic Breast CancerOncologyDec 2026
NCT05686642LT3001Phase 2Acute Ischemic StrokeNeurologyDec 2026
NCT06434597SPH5030Phase 2Biliary Tract or Colorectal Cancer With Her2-positive/MutatedOncologyDec 2026
NCT05872347SPH4336Phase 2Breast Cancer Brain MetastasesOncologyDec 2026
NCT05944224SPH4336Phase 1Advanced Solid TumorsOncologyDec 2026
NCT06214143T3011Phase 1Advanced Solid TumorsOncologyDec 2026
NCT06839131SPH9788Phase 1Healthy ParticipantsOtherDec 2026
NCT06487455SPH7485Phase 1Advanced Solid TumorOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Abbisko Therapeutics Multitude Therapeutics Avistone Biotechnology DualityBio TORL Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.